Second generation

Intake Health Launches Next Generation Revolutionary Hydration Solution For Sports Teams

Retrieved on: 
木曜日, 5月 9, 2024
NFL, NHL, Sport, School, Education, MLS, Second generation, Health, Algorithm, Inflow, NBA, Athlete, Dietary supplement

RALEIGH, N.C., May 9, 2024 /PRNewswire/ -- Intake Health, a leader in health tracking technology, proudly announces the launch of Generation 2 of its InFlow hydration education and awareness solution. Originally developed for elite sports nutrition programs and utilized by nearly half of all major U.S. sports leagues—including the NFL, NHL, NBA, MLS, MLB—as well as many Division I sports teams and international leagues, InFlow is now more accessible than ever. Building on its remarkable success, Generation 2 is set to make a significant impact on a broader range of athletes, extending into colleges and high schools.

Key Points: 
  • RALEIGH, N.C., May 9, 2024 /PRNewswire/ -- Intake Health, a leader in health tracking technology, proudly announces the launch of Generation 2 of its InFlow hydration education and awareness solution.
  • Enhanced by state-of-the-art machine learning models, Generation 2 offers more precise hydration tests.
  • While we started in elite sports, we've worked hard to release a more accessible product that can expand hydration education to more athletes," stated Michael Bender, CEO of Intake Health.
  • As Intake Health continues to redefine the standards of hydration monitoring, we invite educational institutions, sports teams, and the broader athletic community to discover the advantages of our continuous hydration education system.

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
木曜日, 5月 9, 2024
Momentum, IOV, Epidemiology, FDA, Investment, Lung cancer, Intellectual property, Research, National Cancer Institute, Units of paper quantity, ASCO, Endometrial cancer, TIL, Death, Cancer, Food, Second generation, Food and Drug Administration, Safety, Poster, Uterine cancer, PD-1, Next Generation, Melanoma, Marketing, Clinical trial, Investigational New Drug, Cohort, MMR, Information, Patient, Society, Interim, Growth, Pharmaceutical industry

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates. 

Key Points: 
  • Launch Following U.S. Food and Drug Administration (FDA) Approval
    SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates.
  • Iovance remains on track to onboard approximately 50 ATCs by the end of May 2024 and expects to have more than 70 ATCs onboarded by the end of 2024.
  • In the first quarter of 2024, Iovance completed the transfer of marketing authorizations and began distribution of Proleukin.
  • Beginning in the second quarter of 2024, Iovance expects to recognize significant incremental revenues for Proleukin as part of the Amtagvi treatment regimen.

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Retrieved on: 
木曜日, 4月 11, 2024
Patient, BCR, Safety, MMR, TKI, CML, Caregiver, Second generation, Therapy, Acute leukemia, Pharmaceutical industry

BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).

Key Points: 
  • "Similar to our experience with previous successful Phase 1 trials in CML, ELVN-001 looks promising.
  • The preliminary data support that ELVN-001 is a potent and highly selective BCR::ABL1 inhibitor that has activity in heavily pre-treated patients, including post-asciminib patients."
  • “We are thrilled with ELVN-001’s initial Phase 1 data in heavily pre-treated patients with CML,” said Sam Kintz, Co-founder and Chief Executive Officer of Enliven.
  • The discussion will cover details of ELVN-001’s Phase 1 initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.

POLARIS ELEVATES THE BEST-SELLING SIDE-BY-SIDE OF ALL TIME WITH THE 2025 FULL-SIZE RANGER LINEUP

Retrieved on: 
水曜日, 4月 10, 2024
Slate, Smoke, CREW, Metallic, NorthStar, Premium, Lineup, Edition, Durability, Second generation, AWD, LED, Business, EPS, White Lightning, Comfort, RIDE, GPS, Emphasis (typography), Shipbuilding

MINNEAPOLIS, April 10, 2024 /PRNewswire/ -- Polaris Off Road, the world leader in powersports and off-road innovation, today announced a wide range of owner-inspired upgrades to its class-leading full-size RANGER lineup. Building on the already best-selling side-by-side in the industry, the 2025 RANGER lineup features a redesigned front end and new front bumper for added durability, an upgraded Gen 2 transmission for smooth and consistent shifting, and additional factory-installed accessories for added rider value and convenience. In addition to the upgrades, Polaris is introducing the all-new RANGER CREW XP 1000 NorthStar Texas Edition, as well as bringing back a fan favorite – the RANGER CREW XP 1000 Waterfowl Edition.

Key Points: 
  • In addition to the upgrades, Polaris is introducing the all-new RANGER CREW XP 1000 NorthStar Texas Edition, as well as bringing back a fan favorite – the RANGER CREW XP 1000 Waterfowl Edition.
  • The results of that are on display with the full-size RANGER offering for 2025," said Chris Judson, Polaris Vice President and General Manager of Off Road Utility.
  • The 2025 RANGER XP 1000 and XP 1000 NorthStar models come in four color choices including Onyx Black, Blue Slate Metallic Smoke, Sunset Red, and Polaris Pursuit Camo.
  • 2025 RANGER CREW XP 1000 Waterfowl Edition – Starting at $25,499 U.S. MSRP ($30,599 CA MSRP)
    Back and better than ever, Polaris announces the return of the RANGER CREW XP 1000 Waterfowl Edition.

SiMa.ai Secures Funds and Readies New Generative Edge AI Platform

Retrieved on: 
木曜日, 4月 4, 2024
Security, IOT (Internet of Things), Technology, Software, Networks, Artificial Intelligence, Hardware, Speech, GM, Sound, Zebu, Partnership, Deep learning processor, The Next Chapter, Second generation, EDA, Embedded, SVP, Conceptual model, Blog, Business development, Lip-Bu Tan, AI, System, Human, Senior, Architecture, IP, Booth, Maverick Capital, Ecosystem, Machine learning, SNPS, TSMC, Silicon, Medical device

With the release of the second-generation MLSoC, SiMa.ai will unveil one software-centric platform for all edge AI .

Key Points: 
  • With the release of the second-generation MLSoC, SiMa.ai will unveil one software-centric platform for all edge AI .
  • SiMa.ai’s ‘one platform for all edge AI’ scales with customers as their AI/ML journey evolves, from computer vision, to transformers to multimodal generative AI.
  • “AI — particularly the rapid rise of generative AI — is fundamentally reshaping the way that humans and machines work together.
  • For more information on SiMa.ai’s one software-centric platform for all edge AI, please read The Next Chapter at SiMa.ai: One Platform for All Edge AI on the SiMa.ai blog.

AMSOIL Releases New Signature Series 0W-16 100% Synthetic Motor Oil

Retrieved on: 
火曜日, 3月 26, 2024
GM, Second generation, ASTM, Life, Toyota, Carrier oil, AMSOIL, Multimedia, LSPI, 10W-30, Automotive industry

SUPERIOR, Wis., March 26, 2024 /PRNewswire-PRWeb/ -- AMSOIL has launched a new addition to its top-tier Signature Series Synthetic Motor Oil line. New AMSOIL Signature Series 0W-16 100% Synthetic Motor Oil provides next-level engine protection for a new group of drivers, primarily those with Toyota and Honda applications calling for a 0W-16 viscosity.

Key Points: 
  • SUPERIOR, Wis., March 26, 2024 /PRNewswire-PRWeb/ -- AMSOIL has launched a new addition to its top-tier Signature Series Synthetic Motor Oil line.
  • New AMSOIL Signature Series 0W-16 100% Synthetic Motor Oil provides next-level engine protection for a new group of drivers, primarily those with Toyota and Honda applications calling for a 0W-16 viscosity.
  • AMSOIL Signature Series Synthetic Motor Oil provides 75% more engine protection against horsepower loss and wear than required by a leading industry standard,1 extending the life of vital components like pistons and cams.
  • 2 Based on zero LSPI events in five consecutive tests of AMSOIL Signature Series 5W-30 motor oil in the LSPI engine test required by the GM dexos1® Gen 2 specification.

POLARIS TAKES OFF-ROAD RACING'S MOST DOMINANT UTV TO THE NEXT LEVEL WITH GEN 2 RZR PRO R FACTORY

Retrieved on: 
水曜日, 3月 20, 2024
Carbon, Finite element method, FIA, RZR, Carbon-fiber-reinforced polymers, Peter Hancock (professor), Acceleration, Second generation, Comfort, CVT, ATL, GEN, MasterCraft, SAN, ECU, CAD, Heart, Safety, Torque, NASCAR, FEA

MINNEAPOLIS, March 20, 2024 /PRNewswire/ -- Gearing up to defend its dominating 2023 SCORE series Championship season, Polaris Off Road, the leader in off-road vehicle innovation, will unleash the second generation of its championship-proven RZR Pro R Factory at the San Felipe 250. The upgraded iteration boasts an all-new one-piece chassis, comprising a stronger, stiffer frame, a wide range of bodywork upgrades, and new and enhanced electronic componentry. The collective upgrades are the result of ongoing testing, development and refinement between the Polaris team and drivers over the course of the team's 2023 Championship season.

Key Points: 
  • Built upon the revolutionary RZR Pro R platform, the Gen 2 Pro R Factory simply builds on the stock vehicle's optimized fusion of power, strength, and control.
  • While the RZR Pro R Factory features premium, race-enhanced parts, much of the main componentry on the vehicle remains completely stock, based on the revolutionary RZR Pro R platform.
  • MoTeC Components – The naturally aspirated four-cylinder stock ProStar Fury 2.0L remains at the heart of the RZR Pro R Factory.
  • For the 2024 season, Polaris Factory Racing drivers Brock Heger, Cayden MacCachren, Max Eddy Jr., and Craig Scanlon will all be behind the wheel of a new Gen 2 RZR Pro R Factory machine.

SNOWBALL 5.0, LLC, through Alternative Molding Concepts, Broadens Business Portfolio with Strategic Acquisition of Pitbull Tactical, LLC

Retrieved on: 
木曜日, 3月 14, 2024
ACP, Second generation, Tactic, Acquisition, POST, Family, Telescopic sight

POST FALLS, Idaho, March 14, 2024 /PRNewswire-PRWeb/ -- SNOWBALL 5.0, LLC, an Idaho Limited Liability Company and the parent company of Alternative Molding Concepts, proudly announces the acquisition of Pitbull Tactical, LLC, a distinguished leader in home and personal defense technology.

Key Points: 
  • POST FALLS, Idaho, March 14, 2024 /PRNewswire-PRWeb/ -- SNOWBALL 5.0, LLC, an Idaho Limited Liability Company and the parent company of Alternative Molding Concepts, proudly announces the acquisition of Pitbull Tactical, LLC, a distinguished leader in home and personal defense technology.
  • SNOWBALL 5.0, LLC expands its portfolio to encompass not only injection molding services but also advanced personal defense technology with Pitbull Tactical.
  • James Cote, President & Co-Owner at SNOWBALL 5.0, LLC, expressed enthusiasm about the acquisition, stating, "We are thrilled to welcome Pitbull Tactical into the SNOWBALL 5.0 family.
  • With this acquisition, SNOWBALL 5.0, LLC expands its portfolio to encompass not only injection molding services but also advanced personal defense technology with Pitbull Tactical.

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 

Retrieved on: 
水曜日, 2月 28, 2024
IOV, NSCLC, Acquisition, Cohort, Units of paper quantity, Research, MAA, TIL, Information, FDA, Melanoma, Food, Cancer, Growth, U.S. FDA, PD-1, European, Interim, Safety, NDS, Endometrial cancer, Food and Drug Administration, Second generation, Patent, Patient, MMR, Clinical trial, Investment, Intellectual property, Travel, Pharmaceutical industry

SAN CARLOS, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2023 financial results and corporate updates.

Key Points: 
  • The Iovance Cell Therapy Center ( iCTC ) began commercial manufacturing for Amtagvi patients within a week of approval.
  • More than 700 patients have been treated with Iovance TIL therapy manufactured using proprietary Iovance processes as of December 31, 2023.
  • Revenue for the fourth quarter and year ended December 31, 2023, was $0.5 million and $1.2 million, respectively, and comprised of product sales following the Proleukin® acquisition in May 2023.
  • Research and development expenses were $87.5 million for the fourth quarter ended December 31, 2023, an increase of $6.9 million compared to $80.6 million for the same period ended December 31, 2022.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 2月 28, 2024
Fast Track, HCV, BID, Patient, Week, Research, Infection, Tax, Doctor of Philosophy, NS5A, FDA, Food, Security (finance), SVR4, Kinetics, Immunodeficiency, Hospital, Standard of care, Viral, Cirrhosis, Interim, Prevalence, Safety, COVID-19, Contraindication, Death, Administration, Atea, Bemnifosbuvir, Risk, DSMB, Second generation, Development, Ageing, SOC, SVR, Viral load, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • Enrollment of the remainder of this study is ongoing with topline results anticipated in the second half of 2024,” continued Dr. Sommadossi.
  • Final results from the 60 patient lead-in cohort confirmed a 98% SVR4 rate across GT from 58 of 59 patients.
  • Final SVR12 results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $578.1 million at December 31, 2023 compared to $646.7 million at December 31, 2022.